Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$38.98
▼ $0.21 (-0.5%)
Market data updated: 09/20 08:12 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$45.42B
Day Range
$38.66 - $39.38
52-Week Range
$18.21 - $39.70
Beta
—
Next Earnings
03.11.2026
Support
$29.60
Resistance
$39.70
TEVA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+111.3% (1Y)
Strengths: 18/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 183.4%
Growth
Biggest negative driver
Stochastic
%K 83.2 — overbought
Technical
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
67
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
5d ago · $38.72
Evidence: FOMO score jumped from 12 to 38 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
70
$38.10
Now
67
$38.98
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
63
Value
50
Momentum
92
Risk
56
Sentiment
44
Fundamental
64
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Teva Pharmaceutical Industries Limited highlights its financial and strategic initiatives. The company announced plans to issue senior notes through subsidiaries, signaling financial activity. Teva also secured a bid of up to $125 million for BioXcel Therapeutics’ assets in a bankruptcy auction, demonstrating expansion efforts. Additionally, it reported positive Phase IIa trial results for an anti-IL-15 antibody in celiac disease treatment, while S&P Global upgraded its credit rating to BBB-, reflecting improved financial discipline and execution.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Teva Pharmaceutical Industries Limited. News trend score: 44. Reason: 6 of the last 20 articles are negative, versus 5 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
29
🎯 Conviction (vs. Emotion)
43
Psychology
63
Fundamentals
64
Technical
92
Valuation
50
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+24%
Market Narrative
51
Fundamental Reality
43
Narrative Gap
+8
🧠 StockIQ Psychologist
TEVA’s psychology is dominated by **euphoria**, fueled by a 9.4% premium to its 200-day average and universally positive news sentiment, despite flat momentum. The **anchoring** score suggests traders may be fixated on resistance, while **FOMO** hints at cautious urgency from elevated volume. The **narrative gap** (64 vs. 43) implies optimism outpaces tangible fundamentals. The key question: *Will traders sustain euphoria despite weak price momentum, or will anchoring near resistance trigger profit-taking?*
Updated: 09/09/2026, 09:22 AM
What could change this?
👥 What the crowd believes
"S&P Global Ratings upgraded Teva’s long-term issuer credit rating to BBB- from BB+, marking the third upgrade in recent months and reflecting strong execution and financial discipline."
"Teva Pharmaceuticals International GmbH agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics."
"Teva discusses positive topline results for an anti-IL-15 antibody in a Phase IIa celiac disease study."
"Teva announced its intention to issue senior notes through its special purpose finance subsidiaries."
🧠 Market Brain events driving this
📈 13D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 84/100
🔴 Weakest match
Benjamin Graham (Enterprising Investor) — 7/100
🗣️ Why do they disagree?
TEVA’s starkly divided verdicts reflect deep methodological disagreements over growth potential, risk tolerance, and valuation. Peter Lynch’s high score (84) and bullish ‘growth candidate’ label suggest he sees untapped upside in the stock’s fundamentals, while Thorstein Veblen’s alignment with real value creation (69) implies a more measured optimism about its economic contribution. In contrast, Benjamin Graham’s near-total rejection (20) and even his Enterprising Investor variant (7) highlight a stark contrast—Graham’s strict defensive criteria find the stock fundamentally overpriced or risky, whereas Fisher’s low score (40) signals a lack of the long-term quality and growth signature he prized. Meanwhile, market efficiency proponents (45) and Livermore’s neutral stance (60) underscore skepticism that TEVA offers a clear edge over broader indices or trends, while late-cycle warnings from Marks (37) and liquidity concerns from Bagehot (31) frame it as a speculative bet with structural risks.
Peter Lynch
One Up on Wall Street (1989)
🟢 84
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 72
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 69
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 68
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 65
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 64
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 59
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 54
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 53
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 49
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 41
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 40
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 31
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 20
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 10
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 7
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (11 bullish · 1 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
51.8%
Operating Margin
12.5%
Net Margin
8.2%
EBITDA Margin
18.3%
ROE
17.8%
ROA
3.5%
ROIC
—
EPS
$1.23
Cash
$3.56B
Total Debt
$1.80B
Current Ratio
1.04
Debt/Equity
0.23
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$6.80
Tangible Book Value per Share (Tangible NAV)
-$10.21
Sentiment based on basic keywords (not AI) — 5 positive, 9 neutral, 6 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Benzinga · 18.9.2026
Benzinga · 18.9.2026
Benzinga · 18.9.2026
Benzinga · 18.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Benzinga · 15.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 12.9.2026
Insider Monkey · 12.9.2026
MT Newswires · 10.9.2026
Teva Pharmaceutical Industries Limited (TEVA) currently has a StockIQ AI score of 67/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
TEVA currently scores 67/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
TEVA's technical score is 92/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 183.4%; Net income growth: 186.0%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: %K 83.2 — overbought; Return on assets (ROA): 3.5% — weak.
StockIQ has no recorded dividend payment history for TEVA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 13 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Satchi-Fainaro Ronit | Open Market Sale | 21.8.2026 | 111,986 | -415 | $37.25 |
| Weiss Amir | Exercise of Derivative Securities | 21.8.2026 | 7,502 | -2,500 | $19.16 |
| Weiss Amir | Open Market Sale | 21.8.2026 | 13,071 | -6,945 | $37.61 |
| Weiss Amir | Exercise of Derivative Securities | 21.8.2026 | 15,571 | +2,500 | $19.61 |
| Weiss Amir | Open Market Sale | 21.8.2026 | 6,945 | -6,945 | $37.61 |
| Weiss Amir | Exercise of Derivative Securities | 21.8.2026 | 2,500 | -2,500 | $19.16 |
| Satchi-Fainaro Ronit | Open Market Sale | 21.8.2026 | 415 | -415 | $37.25 |
| Weiss Amir | Open Market Sale | 21.8.2026 | 2,500 | -2,500 | $37.63 |
| Weiss Amir | Exercise of Derivative Securities | 21.8.2026 | 2,500 | +2,500 | $19.61 |
| Lippman Evan | Open Market Sale | 17.8.2026 | 18,600 | -18,600 | $36.57 |
| Zaks Tal Zvi | Open Market Sale | 5.8.2026 | 17 | -17 | $34.87 |
| Zaks Tal Zvi | Open Market Sale | 5.8.2026 | 73,247 | -17 | $34.87 |
| Hughes Eric A | Open Market Sale | 3.8.2026 | 25,578 | -25,578 | $34.88 |
| Hughes Eric A | Exercise of Derivative Securities | 3.8.2026 | 52,744 | +52,744 | — |
| Jover Placid | Exercise of Derivative Securities | 3.8.2026 | 12,827 | +12,827 | — |
| Hughes Eric A | Exercise of Derivative Securities | 3.8.2026 | 52,744 | -52,744 | — |
| Jover Placid | Open Market Sale | 3.8.2026 | 12,827 | -12,827 | $34.88 |
| Jover Placid | Exercise of Derivative Securities | 3.8.2026 | 12,827 | -12,827 | — |
| Hughes Eric A | Exercise of Derivative Securities | 3.8.2026 | 160,455 | +52,744 | — |
| Hughes Eric A | Open Market Sale | 3.8.2026 | 134,877 | -25,578 | $34.88 |
| Hughes Eric A | Exercise of Derivative Securities | 3.8.2026 | 0 | -52,744 | — |
| Jover Placid | Exercise of Derivative Securities | 3.8.2026 | 19,601 | +12,827 | — |
| Jover Placid | Open Market Sale | 3.8.2026 | 6,774 | -12,827 | $34.88 |
| Jover Placid | Exercise of Derivative Securities | 3.8.2026 | 25,657 | -12,827 | — |
| Shields Matthew | Open Market Sale | 18.6.2026 | 9,989 | -9,989 | $32.19 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
37,614,253 shares short as of 2026-08-31 · vs. 34,320,980 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
47.5% of trading volume this week was short selling, vs. 48.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology